| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Pharmazz | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $43.22M | Series A | 6/11/2025 | $25M | $216.61M | $5.89 | Sun Pharma | ||||
 | Ring Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $229.04M | Series D | 3/4/2026 | $50M | $300.05M | $2.06 | Undisclosed Investors | ||||
 | Septerna | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225M | Series B | 7/11/2023 | $150M | $313.42M | $1.23 | RA Capital Management, Third Rock Ventures, Samsara BioCapital, Invus, Catalio Capital Management, BVF Partners, Casdin Capital, Logos Capital, Deep Track Capital, Goldman Sachs Asset Management, Vertex Ventures HC, Mirae Asset Financial Group, Direhaus Capital Management, Woodline Partners LP, Soleus Capital | ||||
 | Solve Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $296.39M | Series A | 11/17/2025 | $296.39M | $426.7M | $4.41 | Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, Matrix Capital Management, Decheng Capital, General Atlantic, Surveyor Capital | ||||
 | Tetherex Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.65M | Series B | 4/18/2018 | $63.95M | $366.68M | $21.32 | MPM Capital, Philip Jones | ||||
 | VuMedi | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $80.12M | Series B | 5/14/2025 | $79.98M | $495.24M | $2.11 | Undisclosed Investors | ||||
 | CinCor Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $192.86M | Series B | 10/12/2021 | $142.86M | $370.57M | $4.00 | General Atlantic, Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, Sixty Degree Capital, Sofinnova Investments, Sofinnova Partners, 5AM Ventures, CinRx | ||||
 | IDRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $242.24M | Series B | 8/7/2024 | $120.24M | $414.65M | $6.44 | RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest | ||||
 | Korro Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $593.6M | Series B-2 | 1/5/2022 | $45.12M | $290.4M | $2.78 | Eventide Asset Management, Fidelity, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital, Atlas Venture, NEA, Wu Capital, Qiming Venture Partners, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management, Alexandria Venture Investments | ||||
 | LocanaBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $318M | Series B | 12/14/2020 | $100M | $317.84M | $4.42 | Vida Ventures, RA Capital Management, Invus, Acuta Capital Partners, ARCH Venture Partners, Temasek, Lightstone Ventures, UCB Ventures, GV | ||||
 | Nurx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.87M | Series C-1 | 8/11/2020 | $13.31M | $317.71M | $7.32 | Wittington Ventures, Union Square Ventures, Trustbridge Partners, Kleiner Perkins, Comcast Ventures | ||||
 | Stimwave | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $89.02M | Series E | 8/28/2020 | $3.27M | $235.28M | $16.50 | Undisclosed Investors | ||||
 | Tmunity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $292.52M | Series C | 6/27/2022 | $72.24M | $129.44M | $0.84 | Undisclosed Investors | ||||
 | EndoGastric Solutions | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $377.99M | Series J | 11/25/2020 | $27M | $448.42M | $2.51 | Vertex Growth Fund | ||||
 | Goldfinch Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190.22M | Series B | 6/30/2020 | $105.91M | $252.06M | $1.18 | Eventide Asset Management, Wellington Management Company, Ally Bridge Group, BlackRock, Casdin Capital, Irving Investors, Gilead Sciences, Yonjin Capital, Schroeder Adveq | ||||
 | Heal | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $174.35M | Series E | 10/21/2021 | $4.5M | $134.37M | $0.03 | Undisclosed Investors | ||||
 | One Drop | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $145.63M | Series C | 8/24/2020 | $1.21M | $223.14M | $5.31 | Bayer | ||||
 | PatientPop | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.82M | Series C | 8/25/2020 | $42.65M | $425.93M | $9.93 | HLM Venture Partners, Commonfund, Vivo Capital, Toba Capital, Transformation Capital, Silicon Valley Bank | ||||
 | Twill | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.83M | Series D | 3/17/2021 | $31M | $409.29M | $8.14 | Deerfield Management Company, Omega Capital Partners, ION Crossover Partners | ||||
 | Medly Pharmacy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $297.45M | Series C-1 | 7/29/2022 | $51.86M | $389.1M | $0.20 | Undisclosed Investors | ||||
 | Pact Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $354.6M | Series D | 9/30/2022 | $104.1M | $132.98M | $0.07 | Undisclosed Investors | ||||
 | Pyxis Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $194.5M | Series B | 3/30/2021 | $172.5M | $273.43M | $10.47 | Arix Bioscience, RTW Investments, Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, Tekla Capital Management, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital, Laurion Capital Management, Logos Capital, LifeSci Venture Partners, Leaps by Bayer, Agent Capital, Ipsen Ventures, Longwood Fund, 3E Bioventures | ||||
 | ROME Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $199M | Series B | 9/24/2021 | $149M | $321.94M | $1.49 | Johnson & Johnson Innovation, Bristol Myers Squibb, Eurofarma Ventures, Luma Group, Mirae Asset Capital, Raycap, Sigmas Group, ARCH Ventures, GV, Section 32, Sanofi Ventures, Andreessen Horowitz, Mass General Brigham Ventures, Casdin Capital, Alexandria Venture Investments | ||||
 | Taiga Biotechnologies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $42.83M | Series C | 5/31/2019 | $27.2M | $442.88M | $6.80 | Undisclosed Investors | ||||